Lifeloc Q1 revenue up 6% to $2.28M, net loss $(293k) from $(284k) YoY

Lifeloc Technologies, Inc

2025-Q1 EPS reported -$0.11 revenue$2,277,034

Q1 net revenue $2.277M (+6% YoY); net loss $(293k) or $(0.11) per diluted share.
Gross margin improved to 39.9% from 38.8%; R&D spending >20% of revenue for SpinDx development.
SpinDx beta testing with Anschutz Medical Center imminent; commercial launch targeted for 2026.
Applied for OTCID listing on OTC Markets, effective July 1, 2025, replacing OTC Pink.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.